Novo Nordisk to reduce 9000 jobs in the increasing obesity drug competition

Novo Nordsk, OzemPIC and Wegovy said that he will reduce thousands of global jobs to simplify operations and reserve resources to diabetes and obesity as competitors take the market share.

The company announced on Wednesday that it intends to reduce the global workforce by about 9,000 out of 78,400 jobs in the company, with about 5,000 discounts in its country in the country of Denmark.

The company puts more money and effort on how to sell it for diabetes and obesity and by developing new drugs to target these conditions.

Novo Nordisk to sell weight loss for $ 499 to qualified customers

Discounts will be made throughout the company, including employee areas and headquarters jobs. The company will start notifying employees within the next few months.

Novo Nordisk said that the transformation reflects the company’s commitment to “meet the growing global demand with competition also in the most dynamic and The obesity market driven by the consumer, It is also evident from the latter’s slowdown in growth. ”

Novo Nordisk reduces wegovy prices in half for customers who pay money

The company has acknowledged that rapid expansion in recent years has created greater regulatory complexity and high costs. Job discounts aim to simplify operations and enable the company to invest in science and commercial capabilities and expand the scope of manufacturing, according to Novo Nordsek.

“Our markets are developing, especially in obesity, because they have become more competitive and consumed,” said Novo Nordisk CEO, Mike Dosdar.

The study shows that Eli Lilly’s Zepbound reduces the risk of type 2 diabetes,

ELI Lilly leads to a large extent that the height is in competition It gained the power of the earth Because of its editions of medication for weight loss, Zepbound and Mounjaro. In revenues in the second fiscal quarter have grown to $ 10.4 billion mainly due to both the drug, which have the same active ingredient, tirzepatide, but the different approved uses.

Get Fox Business on the Go by clicking here

Novo Nordisk said it also lost its share in the market due to alternative products that take place by doubling the pharmacies that hurt their profits.